Verdezyne Signs R&D Agreement for Novel Enzymes Gene Development with Syngenta
News Feb 10, 2009
Verdezyne, Inc. has announced it has signed an agreement with Syngenta Biotechnology, Inc. Under the terms of the agreement, Verdezyne will synthesize novel genes, to be tested for optimized expression of enzymes in plants by Syngenta, using its technology platform.
“We are enthusiastic about applying Verdezyne’s technology platform for a leading agribusiness company,” said E. William Radany, Ph.D., President and Chief Executive Officer, Verdezyne. “This relationship is yet another example of the unique power of Verdezyne’s core technology to optimize the expression of key enzymes for the biotechnology marketplace.”
Verdezyne employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel gene libraries for engineering proteins, metabolic pathways, and microorganisms to manufacture platform chemicals and biofuels.
Financial details of the agreement were not disclosed.
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE